Clinical Trials Browser

Phase 2/3 × Hodgkin Disease × camrelizumab × Clear all

NCT04510610 2020-08-12

Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Phase 2/3 Unknown

Hodgkin Disease